{"id":"NCT00670306","sponsor":"AEterna Zentaris","briefTitle":"Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)","officialTitle":"Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: an Open-Labeled Safety and Efficacy Assessment Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2008-05-01","resultsPosted":"2011-01-19","lastUpdate":"2011-04-05"},"enrollment":528,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Benign Prostatic Hypertrophy"],"interventions":[{"type":"DRUG","name":"Cetrorelix Pamoate","otherNames":["Cetrorelix pamoate, D-20762, AEZS-102"]}],"arms":[{"label":"Cetrorelix 78 mg","type":"EXPERIMENTAL"}],"summary":"Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of prostatism by the age of 50 to 80. The purpose of this study is to collect safety and efficacy data for this dosage regimen of cetrorelix pamoate.\n\nFor this study, study medication (Cetrorelix pamoate) is administered by injection in the buttocks (Intramuscular).","primaryOutcome":{"measure":"IPSS Change From Baseline","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Cetrorelix 78 mg","deltaMin":-5.6,"sd":7.1}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"50 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":69,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":528},"commonTop":["Hot flush"]}}